B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies

Release time:2023-02-02

Impact Factor:10.75

DOI number:10.7150/ijbs.66881

Affiliation of Author(s):Xiangya Hospital, Central South University

Teaching and Research Group:Department of Clinical Pharmacology

Journal:Int J Biol Sci

Place of Publication:Australia

Funded by:National Natural Science Foundation of China

Key Words:B.1.617.2; COVID-19; Delta variants; SARS-CoV-2; diagnosis; immune escape; structural biology; transmission; vaccines

Abstract:Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic. With the continuous evolution of the viral genome, SARS-CoV-2 has evolved many variants. B.1.617.2, also called Delta, is one of the most concerned variants. The Delta variant was first reported in India at the end of 2020 but has spread globally, by now, to 135 countries and is not stand still. Delta shared some mutations with other variants, and owned its special mutations on spike proteins, which may be responsible for its strong transmission and increasing virulence. Under these circumstances, a systematic summary of Delta is necessary. This review will focus on the Delta variant. We will describe all the characteristics of Delta (including biological features and clinical characteristics), analyze potential reasons for its strong transmission, and provide potential protective ways for combating Delta.

First Author:Yan Zhan, Hui Yin

Indexed by:Review

Correspondence Author:Ji-Ye Yin

Discipline:Medicine

First-Level Discipline:Pharmaceutical Science

Document Type:J

Volume:18

Issue:5

Page Number:1844-1851

ISSN No.:1449-2288

Translation or Not:no

Date of Publication:2022-02-14

Included Journals:SCI

Links to published journals:https://www.ijbs.com/v18p1844.htm